Rizzo, Manfredi2024-03-272024-03-272023204-2023.164https://repository.mbru.ac.ae/handle/1/1439Introduction: Obesity is a highly prevalent chronic disease characterized by an increase of body fat stores.1 Increased adiposity (body fat), particularly abdominal/visceral fat, plays a role in altering immune and inflammatory function, developing insulin resistance (IR) and contributing to downstream metabolic risk factors (RFs) such as hyperglycemia, dyslipidemia, systemic adrenergic activity, hypertension, atherosclerosis and finally, cardiovascular (CV) disease (CVD).2 Furthermore, visceral fat is strongly associated with increased atherosclerotic burden and the risk of recurrent atherosclerotic CVD (ASCVD), residual CV risk, and CVD mortality.enGlucagon-like peptide 1 receptor agonistsDual glucagon-like peptide 1/gastric inhibitoryPeptide receptor agonistsAtherosclerotic cardiovascular diseaseOverweightObesityArticle